Use and Prognostic Implications of Cardiac Troponin in COVID-19

Laura De Michieli; Allan S Jaffe; Yader Sandoval

doi:10.1016/j.hfc.2022.08.005

Use and Prognostic Implications of Cardiac Troponin in COVID-19

Heart Fail Clin. 2023 Apr;19(2):163-176. doi: 10.1016/j.hfc.2022.08.005.

Authors

Laura De Michieli¹, Allan S Jaffe², Yader Sandoval³

Affiliations

¹ Department of Cardiovascular Diseases, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Via Giustiniani 2, Padova 35128, Italy.
² Department of Cardiovascular Diseases, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.
³ Department of Cardiovascular Diseases, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA. Electronic address: sandoval.yader@mayo.edu.

Abstract

Myocardial injury is common in patients with COVID-19 and is associated with an adverse prognosis. Cardiac troponin (cTn) is used to detect myocardial injury and assist with risk stratification in this population. SARS-CoV-2 infection can play a role in the pathogenesis of acute myocardial injury due to both direct and indirect damage to the cardiovascular system. Despite the initial concerns about an increased incidence of acute myocardial infarction (MI), most cTn increases are related to chronic myocardial injury due to comorbidities and/or acute nonischemic myocardial injury. This review will discuss the latest findings on this topic.

Keywords: COVID-19; Cardiac troponin; High sensitivity cardiac troponin; Myocardial injury; Prognosis; Risk stratification.

Publication types

Review

MeSH terms

COVID-19* / complications
Humans
Myocardial Infarction* / diagnosis
Prognosis
SARS-CoV-2
Troponin

Substances

Troponin